Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Laura Hüser

Showing results (1-10 of 26) with videos related to

Pageof 3
Sort By:
Oncotarget|March 23, 2019
Role of STAT3 dependent SOX2 and CD24 expression in melanoma cell adaptive resistance towards targeted therapiesLaura Hüser, Peter Altevogt, Jochen Utikal
International Journal of Cancer|August 14, 2020
Novel insights into the function of CD24: A driving force in cancerPeter Altevogt, Marei Sammar, Laura Hüser, et al.
Expert Opinion on Therapeutic Targets|October 28, 2018
Targeting SOX2 in anticancer therapyLaura Hüser, Daniel Novak, Viktor Umansky, et al.
Cancers|November 21, 2018
Targeted Therapy-Resistant Melanoma Cells Acquire Transcriptomic Similarities with Human MelanoblastsLionel Larribère, Silke Kuphal, Christos Sachpekidis, et al.
Seminars in Cancer Biology|August 15, 2019
SOX2 in development and cancer biologyDaniel Novak, Laura Hüser, Jonathan J Elton, et al.
The Journal of Comparative Neurology|January 30, 2015
Morphology and connectivity of the small bistratified A8 amacrine cell in the mouse retinaSammy C S Lee, Arndt Meyer, Timm Schubert, et al.
Oncotarget|January 5, 2018
New role of ID3 in melanoma adaptive drug-resistanceSachindra, Lionel Larribère, Daniel Novak, et al.
Purinergic Signalling|December 16, 2014
NTPDase2 and the P2Y1 receptor are not required for mammalian eye formationKristine Gampe, Silke Haverkamp, Simon C Robson, et al.
Frontiers in Cellular Neuroscience|January 25, 2024
Spike desensitisation as a mechanism for high-contrast selectivity in retinal ganglion cellsLe Chang, Yanli Ran, Mingpo Yang, et al.
International Journal of Cancer|June 16, 2018
SOX2-mediated upregulation of CD24 promotes adaptive resistance toward targeted therapy in melanomaLaura Hüser, Sachindra Sachindra, Karol Granados, et al.
Pageof 3

Showing results (1-10 of 26) with videos related to

Sort By:
Pageof 3
Oncotarget|March 23, 2019
Role of STAT3 dependent SOX2 and CD24 expression in melanoma cell adaptive resistance towards targeted therapiesLaura Hüser, Peter Altevogt, Jochen Utikal
International Journal of Cancer|August 14, 2020
Novel insights into the function of CD24: A driving force in cancerPeter Altevogt, Marei Sammar, Laura Hüser, et al.
Expert Opinion on Therapeutic Targets|October 28, 2018
Targeting SOX2 in anticancer therapyLaura Hüser, Daniel Novak, Viktor Umansky, et al.
Cancers|November 21, 2018
Targeted Therapy-Resistant Melanoma Cells Acquire Transcriptomic Similarities with Human MelanoblastsLionel Larribère, Silke Kuphal, Christos Sachpekidis, et al.
Seminars in Cancer Biology|August 15, 2019
SOX2 in development and cancer biologyDaniel Novak, Laura Hüser, Jonathan J Elton, et al.
The Journal of Comparative Neurology|January 30, 2015
Morphology and connectivity of the small bistratified A8 amacrine cell in the mouse retinaSammy C S Lee, Arndt Meyer, Timm Schubert, et al.
Oncotarget|January 5, 2018
New role of ID3 in melanoma adaptive drug-resistanceSachindra, Lionel Larribère, Daniel Novak, et al.
Purinergic Signalling|December 16, 2014
NTPDase2 and the P2Y1 receptor are not required for mammalian eye formationKristine Gampe, Silke Haverkamp, Simon C Robson, et al.
Frontiers in Cellular Neuroscience|January 25, 2024
Spike desensitisation as a mechanism for high-contrast selectivity in retinal ganglion cellsLe Chang, Yanli Ran, Mingpo Yang, et al.
International Journal of Cancer|June 16, 2018
SOX2-mediated upregulation of CD24 promotes adaptive resistance toward targeted therapy in melanomaLaura Hüser, Sachindra Sachindra, Karol Granados, et al.
Pageof 3